Filing Details
- Accession Number:
- 0000925421-18-000292
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-08-16 16:18:10
- Reporting Period:
- 2018-08-14
- Accepted Time:
- 2018-08-16 16:18:10
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1420565 | Aileron Therapeutics Inc | ALRN | Pharmaceutical Preparations (2834) | V8 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1114448 | Ag Novartis | Lichtstrasse 35 Basel V8 CH 4056 | No | No | Yes | No | |
1297709 | Ltd Bioventures Novartis | C/O Novartis International Ag Wsj-200.220 Basel V8 CH-4002 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2018-08-14 | 3,300 | $2.26 | 2,437,413 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-08-15 | 2,635 | $2.15 | 2,434,778 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Reflects sales of common stock executed in multiple transactions at prices ranging from $2.17 to $2.33. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $2.13 to $2.25. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.